{"id":20475,"date":"2025-12-21T17:26:11","date_gmt":"2025-12-21T16:26:11","guid":{"rendered":"https:\/\/drugprevent.org.uk\/ppp\/?p=20475"},"modified":"2026-03-10T21:11:09","modified_gmt":"2026-03-10T20:11:09","slug":"civil-society-perspectives-on-the-eu-drugs-strategy","status":"publish","type":"post","link":"https:\/\/drugprevent.org.uk\/ppp\/2025\/12\/civil-society-perspectives-on-the-eu-drugs-strategy\/","title":{"rendered":"Civil Society Perspectives on the EU Drugs Strategy"},"content":{"rendered":"
<\/div>\n
\n

Opening statement by NDPA:<\/strong><\/span><\/p>\n

NDPA has mixed feelings about Harm Reduction – in one form, aiming to minimise harm in users while they consider cessation of drug use, it is something which NDPA supports, but in another form it is a ‘closet legalisation ploy’ – promoting the notion that drug use is valid and one should only seek to reduce the harm users experience – and NDPA clearly does not support this form. With this caveat, this article is included as an opinion piece for reading.<\/strong><\/span><\/p>\n

by\u00a0Ricardo Fuertes, EATG member and representative at the EU Civil Society Forum on Drugs – December 17, 2025<\/span><\/p>\n

Earlier this month, Mr Fuertes participated in the Civil Society Forum on Drugs\u00a0as a representative of EATG. The discussions offered important insights into the current direction of EU drug policy and the conditions under which civil society organisations are operating.<\/span><\/p>\n

\n

The New EU Drugs Strategy: An Unbalanced Approach and the Downgrading of Harm Reduction<\/strong><\/span><\/h3>\n

The European Commission presented the new\u00a0EU Drugs Strategy. From the perspective of many civil society organisations, the Strategy is notably unbalanced. While prevention, treatment, and social integration are clearly highlighted and structured as core pillars, harm reduction is treated differently. Rather than being recognised as a distinct and essential pillar, it is dispersed across the document, diluted in its language, and separated from the other approaches.<\/span><\/p>\n

At the same time, the Strategy is highly detailed when it comes to security-related themes, threats, and supply reduction. Considerable attention is given to law enforcement and control measures, while approaches grounded in public health and human rights receive comparatively less emphasis. Decriminalisation and the legal regulation of drugs are entirely absent from the framework. In addition, the Strategy lacks a defined timeframe or end date, raising concerns about accountability and evaluation. It is also not accompanied by a dedicated budget or a comprehensive action plan beyond an\u00a0Action Plan\u00a0against drug trafficking.<\/span><\/p>\n

These concerns have been explicited in a\u00a0joint letter\u00a0coordinated by the International Drug Policy Consortium and signed by a wide number of organisations,\u00a0including EATG, as a tool to encourage negotiation with Member States.<\/span><\/p>\n

\n

Systemic Barriers and Excluded Populations<\/strong><\/span><\/h3>\n

Discussions throughout the Forum highlighted the need to better address systemic barriers affecting vulnerable populations. While HIV and viral hepatitis are mentioned within the EU Drugs Strategy, this is done in broad terms, without clearly identifying who is being left behind and why.<\/span><\/p>\n

From EATG\u2019s perspective, undocumented migrants must be explicitly included in prevention and treatment efforts. Legal precarity, fear of detection, and administrative barriers continue to exclude many undocumented migrants from access to drug services, HIV prevention, and care for viral hepatitis. A generic commitment to identifying systemic barriers is not sufficient; concrete measures are needed to ensure that prevention and treatment are accessible to all, regardless of migration status.<\/span><\/p>\n

\n

Civil Society Participation Under Pressure<\/strong><\/span><\/h3>\n

A noticeable decline in participation at this year\u2019s Forum was also observed. This reflects the increasingly difficult conditions under which many civil society organisations are operating across Europe. Participants reported funding cuts, staff reductions and layoffs, as well as decisions to limit participation in international meetings. These pressures are forcing organisations to reduce activities and service provision, with harm reduction particularly affected.<\/span><\/p>\n

Across the Forum, there was a shared sense that civil society space is narrowing and that critical voices are at risk of being marginalised.<\/span><\/p>\n

As debates around the EU Drugs Strategy continue, EATG will continue to underline the importance of protecting civil society space, restoring harm reduction as a central pillar of drug policy, and ensuring that prevention and treatment genuinely reach the most marginalised, including undocumented migrants. A balanced, public health- and rights-based approach is not an abstract principle; it requires concrete actions, political commitment, and sustained investment.<\/span><\/p>\n

\n

\"\"<\/a><\/figure>\n

\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Photo: Delegates at the Civil Society Forum on Drugs – December 17, 2025<\/span><\/p>\n

Source:\u00a0 https:\/\/www.eatg.org\/blogs\/the-new-eu-drugs-strategy-an-unbalanced-approach-and-the-downgrading-of-harm-reduction\/<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Opening statement by NDPA: NDPA has mixed feelings about Harm Reduction – in one form, aiming to minimise harm in users while they consider cessation of drug use, it is something which NDPA supports, but in another form it is a ‘closet legalisation ploy’ – promoting the notion that drug use is valid and one […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[129,68,17,141,40,139,36],"tags":[],"class_list":["post-20475","post","type-post","status-publish","format-standard","hentry","category-culture","category-drug-use-various-effects","category-europe-uk","category-harm-reduction-research","category-prevention-research","category-strategy-and-policy","category-treatment-addiction"],"_links":{"self":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/comments?post=20475"}],"version-history":[{"count":4,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20475\/revisions"}],"predecessor-version":[{"id":20480,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20475\/revisions\/20480"}],"wp:attachment":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/media?parent=20475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/categories?post=20475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/tags?post=20475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}